Promising
Cerebrolysin
The prediction game
Call it: rising or fading?
Where does Cerebrolysin stand 12 months from now? Lock your call with a confidence level. When the window closes, the Brier rule scores your calibration: right and confident earns the most, wrong and confident costs the most. Points and a leaderboard spot are the whole prize. No stakes, no money.
One call per intervention. It locks the moment you submit: no edits, no cancels. It resolves when the 12-month window closes.
The Crowd’s Call
Rising or fading over the next 12 months? Lock your call and find out if you saw it coming.
Community Signal
No weigh-ins yet. Be the first and set the early signal.
Evidence
Evidence grade: C (mixed evidence)
Graded from the strength of the published research, independent of any verdict on this page.
Evidence Anchor
BioHarmony 6.3/10
Cerebrolysin lands at Neutral because it pairs the largest human trial base of any nootropic-adjacent peptide with an evidence story that independent reviewers do not confirm, plus a heavy infusion burden. If you are investigating acute neuro-recovery, severe stroke or moderate-to-severe brain injury, and you can access supervised clinic infusions and verified product, it is a reasonable thing to research with a clinician. If you are a healthy person hoping for a cognitive edge, the data is simply not there, and the effort and sourcing risk are high. The two real-world frictions that decide most cases are the IV or IM infusion burden and the grey-market sterility risk of an injectable biological. ✅ Best for: People investigating recovery from severe ischemic stroke, where the severe subgroup showed the clearest signal, who are working with a clinician. People dealing with moderate-to-severe traumatic brain injury who can access supervised infusion courses, since that is one of its better-supported uses, per Muresanu et al. 2020. Patients in countries where it is approved and supplied through a real pharmacy rather than imported. Anyone who can verify they have genuine EVER Pharma product and a clinical setting for sterile administration. Researchers and informed users who understand the evidence is split and want the recovery context, not an enhancement promise. ❌ Avoid if: You are a healthy person seeking cognitive enhancement, since there is no trial showing benefit in a well brain and the burden is high. You have a known allergy or hypersensitivity to biological or animal-derived products, given the foreign-protein anaphylaxis risk. You have active or suspected cancer, where a growth-factor-mimicking biological is unwise without specialist guidance. You cannot source verified product and would be relying on grey-market vials, because sterility, cold-chain, and counterfeit risk for an injectable can exceed the compound's own risk. You want a low-effort routine, because repeated multi-week clinic infusions are the opposite of that.
Read the full BioHarmony report
My score and my verdict: one signal of three, never the whole answer.
Momentum
Signals begin with Edition 2
Direction needs two weekly snapshots to compare, so the arrows stay off until the next edition. Attention tracking is already running.
Momentum = how fast attention is rising across search, Reddit, PubMed, podcasts, and curated industry newsletters this week; it can flag an item as Overhyped/Fading, but it never overrides the evidence behind Proven. How momentum works.
- Ring
- Promising
- Trend
- Begins with Edition 2
- Momentum
- 2.5%
- BioHarmony Score
- 6.3/10
- Last Updated
- Jul 2, 2026
Sources
- BioHarmony score
- Search trend delta
- Reddit velocity
- PubMed publication count
- Podcast mention frequency
- Curated newsletter mentions
The score anchors the ring; the other five drive momentum, which can nudge the ring by one step at most. How placement works.
Weigh In
Your input feeds the community signal shown beside my verdict. It informs the board and it never sets the score by itself. How community input works.
New voice here? We send a one-tap verification link so every entry comes from a real person. Signed-in members skip this.